» Articles » PMID: 35959923

Identification of a Novel Pseudo-Natural Product Type IV IDO1 Inhibitor Chemotype

Overview
Specialty Chemistry
Date 2022 Aug 12
PMID 35959923
Authors
Affiliations
Soon will be listed here.
Abstract

Natural product (NP)-inspired design principles provide invaluable guidance for bioactive compound discovery. Pseudo-natural products (PNPs) are de novo combinations of NP fragments to target biologically relevant chemical space not covered by NPs. We describe the design and synthesis of apoxidoles, a novel pseudo-NP class, whereby indole- and tetrahydropyridine fragments are linked in monopodal connectivity not found in nature. Apoxidoles are efficiently accessible by an enantioselective [4+2] annulation reaction. Biological evaluation revealed that apoxidoles define a new potent type IV inhibitor chemotype of indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme considered a target for the treatment of neurodegeneration, autoimmunity and cancer. Apoxidoles target apo-IDO1, prevent heme binding and induce unique amino acid positioning as revealed by crystal structure analysis. Novel type IV apo-IDO1 inhibitors are in high demand, and apoxidoles may provide new opportunities for chemical biology and medicinal chemistry research.

Citing Articles

Immunometabolism: signaling pathways, homeostasis, and therapeutic targets.

Xu R, He X, Xu J, Yu G, Wu Y MedComm (2020). 2024; 5(11):e789.

PMID: 39492834 PMC: 11531657. DOI: 10.1002/mco2.789.


Identification of a Monovalent Pseudo-Natural Product Degrader Class Supercharging Degradation of IDO1 by its native E3 KLHDC3.

Hennes E, Lucas B, Scholes N, Cheng X, Scott D, Bischoff M bioRxiv. 2024; .

PMID: 39026748 PMC: 11257573. DOI: 10.1101/2024.07.10.602857.


Synthesis of Complex Tetracyclic Fused Scaffolds Enabled by (3 + 2) Cycloaddition.

Porte V, van Veen B, Zhang H, Piacentini P, Armentia Matheu S, Woolford S Org Lett. 2024; 26(23):4873-4876.

PMID: 38820198 PMC: 11187634. DOI: 10.1021/acs.orglett.4c01269.


Discovery of the sEH Inhibitor Epoxykynin as a Potent Kynurenine Pathway Modulator.

Dotsch L, Davies C, Hennes E, Schonfeld J, Kumar A, Guita C J Med Chem. 2024; 67(6):4691-4706.

PMID: 38470246 PMC: 10983002. DOI: 10.1021/acs.jmedchem.3c02245.


Identification of a Novel Pseudo-Natural Product Type IV IDO1 Inhibitor Chemotype.

Davies C, Dotsch L, Ciulla M, Hennes E, Yoshida K, Gasper R Angew Chem Int Ed Engl. 2022; 61(40):e202209374.

PMID: 35959923 DOI: 10.1002/anie.202209374.

References
1.
Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

2.
Nguyen N, Nakahama T, Le D, Son L, Chu H, Kishimoto T . Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014; 5:551. PMC: 4212680. DOI: 10.3389/fimmu.2014.00551. View

3.
Tan L, Yu J, Tan L . The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012; 323(1-2):1-8. DOI: 10.1016/j.jns.2012.08.005. View

4.
Balog A, Lin T, Maley D, Gullo-Brown J, Kandoussi E, Zeng J . Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor. Mol Cancer Ther. 2020; 20(3):467-476. DOI: 10.1158/1535-7163.MCT-20-0251. View

5.
Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld J . Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2014; 3(2):161-72. DOI: 10.1158/2326-6066.CIR-14-0137. View